Vaccine innovation model: A technology transfer perspective in pandemic contexts.
Vaccine
; 40(33): 4748-4763, 2022 08 05.
Article
in English
| MEDLINE | ID: covidwho-1907854
ABSTRACT
This work identifies the innovations that made it possible for the Bio-Manguinhos/Fiocruz Immunobiological Technology Institute to engage in the entire production of the Oxford/AstraZeneca vaccine (ChAdOx1 nCov-19) in Brazil, just 1.8 years after the COVID-19 pandemic was declared. The results were summarized in a case-based innovation model composed of 11 workstreams, 32 stages, 22 gates, 11 innovations, and 38 events. In terms of research contributions, three were found (i) the identification of firm and government-level innovations allowing the substantial reduction in the COVID-19 vaccine time-to-market in Brazil; (ii) the presentation of empirical evidence supporting the new Outbreak Paradigm for vaccine research, development, and production; and (iii) the proposition of a conceptual model for describing innovations through the vaccine value chain in pandemic contexts, particularly when technology transfer is involved.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Vaccines
/
COVID-19
Type of study:
Observational study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Vaccine
Year:
2022
Document Type:
Article
Affiliation country:
J.vaccine.2022.06.054
Similar
MEDLINE
...
LILACS
LIS